Hu C, Xie J, Fei X, Sun Y, Lei S, Yan X
Discov Oncol. 2025; 16(1):60.
PMID: 39827419
PMC: 11743407.
DOI: 10.1007/s12672-025-01799-7.
Lavallee E, Roulet-Matton M, Giang V, Cardona Hurtado R, Chaput D, Gravel S
Life Sci Alliance. 2024; 8(3).
PMID: 39658088
PMC: 11632064.
DOI: 10.26508/lsa.202402912.
Gregory M, Ofosu-Asante K, Lazarte J, Puente P, Tawfeeq N, Belony N
PLoS One. 2024; 19(10):e0312563.
PMID: 39436906
PMC: 11495567.
DOI: 10.1371/journal.pone.0312563.
Wu W, Zhu J, Nihira N, Togashi Y, Goda A, Koike J
Breast Cancer Res. 2024; 26(1):146.
PMID: 39434131
PMC: 11492477.
DOI: 10.1186/s13058-024-01901-x.
Rodriguez-Sarmiento D, Rondon-Villarreal P, Scarpelli-Pereira P, Bouvier M
Biomolecules. 2024; 14(8).
PMID: 39199311
PMC: 11352469.
DOI: 10.3390/biom14080923.
The use of matrine to inhibit osteosarcoma cell proliferation via the regulation of the MAPK/ERK signaling pathway.
Huang X, Zeng J, Ruan S, Lei Z, Zhang J, Cao H
Front Oncol. 2024; 14:1338811.
PMID: 39161382
PMC: 11330765.
DOI: 10.3389/fonc.2024.1338811.
EGFR mutations induce the suppression of CD8 T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.
Huang H, Zhu X, Yu Y, Li Z, Yang Y, Xia L
J Transl Med. 2024; 22(1):653.
PMID: 39004699
PMC: 11246587.
DOI: 10.1186/s12967-024-05456-5.
Phosphorylation of caspase-8 by RSKs via organ-constrained effects controls the sensitivity to TNF-induced death.
He P, Ai T, Qiao M, Yang Z, Han J
Cell Death Discov. 2024; 10(1):255.
PMID: 38789425
PMC: 11126741.
DOI: 10.1038/s41420-024-02024-0.
Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion.
Lazarte J, Lamango N
Biomedicines. 2024; 12(3.
PMID: 38540084
PMC: 10968070.
DOI: 10.3390/biomedicines12030470.
p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
Yassin-Kassab A, Chatterjee S, Khan N, Wang N, Sandulache V, Huang E
BMC Cancer. 2024; 24(1):233.
PMID: 38373988
PMC: 10875868.
DOI: 10.1186/s12885-024-11892-9.
Using Flavonoid Substitution Status to Predict Anticancer Effects in Human Melanoma Cancers: An In Vitro Study.
Jakimiuk K, Szoka L, Surazynski A, Tomczyk M
Cancers (Basel). 2024; 16(3).
PMID: 38339241
PMC: 10854695.
DOI: 10.3390/cancers16030487.
RSK3 switches cell fate: from stress-induced senescence to malignant progression.
Huna A, Flaman J, Lodillinsky C, Zhu K, Makulyte G, Pakulska V
J Exp Clin Cancer Res. 2023; 42(1):318.
PMID: 38008756
PMC: 10680185.
DOI: 10.1186/s13046-023-02909-5.
Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs.
Chang Y, Wu C, Cheng C, Chen J, Chang L
Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895906
PMC: 10610195.
DOI: 10.3390/ph16101435.
Neuropilin-2 acts a critical determinant for epithelial-to-mesenchymal transition and aggressive behaviors of human head and neck cancer.
Ahn M, Kim J, Choi S, Kim H, Park D, Oh K
Cell Oncol (Dordr). 2023; 47(2):497-511.
PMID: 37787967
DOI: 10.1007/s13402-023-00878-7.
High-throughput screening identifies cell cycle-associated signaling cascades that regulate a multienzyme glucosome assembly in human cells.
Schmitt D, Dranchak P, Parajuli P, Blivis D, Voss T, Kohnhorst C
PLoS One. 2023; 18(8):e0289707.
PMID: 37540718
PMC: 10403072.
DOI: 10.1371/journal.pone.0289707.
Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C, Wendlinger S, Niessner H, Siewert J, Sinnberg T, Hofmann A
J Exp Clin Cancer Res. 2023; 42(1):175.
PMID: 37464364
PMC: 10354913.
DOI: 10.1186/s13046-023-02755-5.
The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.
Weidenauer K, Schmidt C, Rohde C, Pauli C, Blank M, Heid D
Leukemia. 2023; 37(8):1611-1625.
PMID: 37414921
PMC: 10400424.
DOI: 10.1038/s41375-023-01951-8.
Evaluation of Pathogenicity and Structural Alterations for the Mutations Identified in the Conserved Region of the C-Terminal Kinase Domain of Human-Ribosomal S6 Kinase 1.
Chikhale V, Goswami N, Khan M, Borah P, Varma A
ACS Omega. 2023; 8(18):16273-16283.
PMID: 37179615
PMC: 10173430.
DOI: 10.1021/acsomega.3c00722.
Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N, Lazarte J, Jin Y, Gregory M, Lamango N
Oncotarget. 2023; 14():243-257.
PMID: 36961909
PMC: 10038354.
DOI: 10.18632/oncotarget.28390.
Activation and inhibition of the C-terminal kinase domain of p90 ribosomal S6 kinases.
Fruergaard M, Nielsen C, Kjeldsen C, Iversen L, Andersen J, Nissen P
Life Sci Alliance. 2023; 6(5).
PMID: 36806093
PMC: 9941302.
DOI: 10.26508/lsa.202201425.